Psilocybin for OCD — is there real clinical evidence?

The research is real but limited. The earliest controlled study (Moreno et al., 2006, University of Arizona) gave psilocybin to 9 OCD patients in a randomized crossover design. All 9 showed reductions in OCD symptoms at all dose levels, including very low doses. The results were striking and have held up to scrutiny — but the sample is tiny. Johns Hopkins and NYU have OCD studies either published or in progress as of 2025-26.

The theoretical mechanism that explains OCD response: OCD involves hyperactive cortico-striato-thalamo-cortical (CSTC) loops — essentially the same kind of rigid, stuck pattern that psilocybin disrupts via the serotonin 2A receptor. Loosening these loops, even briefly, may interrupt the compulsion cycle. This is the same basic logic as ketamine for depression — temporary disruption of pathological rigidity can provide lasting benefit.

Important caveat: some people with OCD find high-dose psilocybin amplifies intrusive thoughts rather than quieting them. Individual response varies more for OCD than for depression. If you have OCD and want to explore psilocybin, a clinical trial or experienced facilitator who knows OCD is critical. Don't self-treat at high doses without understanding this risk.